Endo says CFO, COO to leave the company; Lilly sues Perrigo for challenging Axiron patent;

@FiercePharma: U.K. cost watchdog about-faces on BMS and AZN's Forxiga, recommending it for some diabetes patients. Story | Follow @FiercePharma

@EricPFierce: Will Hospira never learn? FDA warning letter says some problems at India plant same as those recently noted at Rocky Mount. More | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: FDA is importing TPN to ease drug shortage. Story | Follow @CarlyHFierce

> Endo Health Solutions ($ENDP) said two of its top executives, CFO Alan G. Levin and COO Julie McHugh, are leaving the company; no replacements have yet been named. Release | Report

> Eli Lilly ($LLY) sued Perrigo ($PRGO) for infringing its patent on the low-testosterone treatment Axiron, seeking to block generic versions of the drug. Report

> Pfizer ($PFE) issued $4 billion in bonds, in its first dollar-denominated debt issue since 2009. Report

> Analysts hiked their price targets on Valeant Pharmaceuticals ($VRX) on the strength of its newly agreed acquisition of Bausch + Lomb. Report

> Royalty Pharma contends that recent stock sales by Elan ($ELN) investors signal that shareholders support its buyout proposal. Report

> Germany's Stada Arzneimittel said it successfully placed €350 million worth of corporate bonds. Report

Medical Device News

@FierceMedDev: GE snags ultrasound repair business. More | Follow @FierceMedDev

 @DamianFierce: As GSK trumpets two new FDA approvals, France's bioMérieux is poised to cash in on companion diagnostics. More | Follow @DamianFierce

@MichaelGFierce: Devicemakers balk at FDA's recall guidelines. Item | Follow @MichaelGFierce

> Sequenom reaches into France with prenatal Dx. Report

> GE snags ultrasound repair business. Article

> Devicemakers balk at FDA's recall guidelines. More

> Edwards hit with FDA warning letter. News

> Abbott's Absorb takes India by storm. Story

Biotech News

@FierceBiotech: UCLA slams the door on GlaxoSmithKline's latest R&D competition. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: Updated: GlaxoSmithKline gains FDA OK on two genetically targeted melanoma drugs. Report | Follow @JohnCFierce

@RyanMFierce: Biogen Idec appears to be playing the long game with delayed EU launch of Tecfidera, and that could benefit even short-term investors. | Follow @RyanMFierce

 @EmilyMFierce: Newest feature at @FierceBiotech: Top 10 experimental cancer drugs - 2013. Special Report | Follow @EmilyMFierce

> San Diego biotech files $23M IPO for gastroparesis PhIII. Report

> Pfizer taps UCSF for small-molecule drug discovery. Story

> ASCO presentations portend future shock of immunotherapy drug prices. Article

> Elan execs ready fallback plan as Royalty attacks 'jumble' of deals. News

Pharma Manufacturing News

> Pfizer sells King Pharma plant to UPM Pharmaceuticals. More

> UCB sells New York plant to Unither. News

> FDA turns to Fresenius to help relieve TPN shortage. Story

> New problems with Hospira's Indian plant reminiscent of Rocky Mount. Article

> J&J appeals OTC plant license revocation in India. Item

Vaccines News

> H7N9 shows resistance to Roche's Tamiflu. News

> Chinese HFMD vaccine impresses in Phase III. Report

> Gates-inspired gene therapy gives pandemic protection. Story

> Study links GSK's swine flu vaccine to narcolepsy in adults. Article

> Researchers seek fresh approach to HIV vaccine. More

And Finally... A new analysis from the American Medical Association found that children who have used ADHD treatments are no less likely to abuse drugs later in life than those who haven't. Report